Literature DB >> 11160029

Herpes zoster--predicting and minimizing the impact of post-herpetic neuralgia.

R Johnson1.   

Abstract

Herpes zoster results from reactivation of latent varicella-zoster virus in the dorsal root ganglia and is frequently associated with severe pain. Most patients suffer acute pain during the rash phase, and in many, prodromal pain or discomfort also precedes the rash. The pain of herpes zoster gradually resolves with time, but may persist after the acute disease as post-herpetic neuralgia for weeks, months or even years. Post-herpetic neuralgia, the most common complication of herpes zoster, often results in significant morbidity and healthcare resource usage. Early treatment with oral antivirals has been shown to accelerate the resolution of postherpetic neuralgia, with therapeutic effects particularly evident in the over-50 age group, where pain generally persists for longer. Progressively increasing life expectancy of the population translates to increasing numbers of cases of herpes zoster. The socio-economic gains associated with active management, including use of oral antivirals where indicated, to speed resolution of pain and post-herpetic neuralgia, readily justify additional cost.

Entities:  

Mesh:

Year:  2001        PMID: 11160029     DOI: 10.1093/jac/47.suppl_1.1

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.

Authors:  Ralph P Insinga; Robbin F Itzler; James M Pellissier
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Natural history of pain following herpes zoster.

Authors:  Hans Gustav Thyregod; Michael C Rowbotham; Michelle Peters; Jessica Possehn; Marlene Berro; Karin Lottrup Petersen
Journal:  Pain       Date:  2006-10-27       Impact factor: 6.961

3.  Effect of viral load on the outcome of herpes zoster.

Authors:  M L Quinlivan; K Ayres; H Ran; S McElwaine; M Leedham-Green; F T Scott; R W Johnson; J Breuer
Journal:  J Clin Microbiol       Date:  2007-09-12       Impact factor: 5.948

Review 4.  An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy.

Authors:  Che S Zin; Lisa M Nissen; Maree T Smith; James P O'Callaghan; Brendan J Moore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 5.  Analgesic therapy in postherpetic neuralgia: a quantitative systematic review.

Authors:  Kathleen Hempenstall; Turo J Nurmikko; Robert W Johnson; Roger P A'Hern; Andrew S C Rice
Journal:  PLoS Med       Date:  2005-07-26       Impact factor: 11.069

6.  Increasing trends of herpes zoster in Australia.

Authors:  Raina MacIntyre; Alicia Stein; Christopher Harrison; Helena Britt; Abela Mahimbo; Anthony Cunningham
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

7.  Healthcare Resource Utilisation Associated with Herpes Zoster in a Prospective Cohort of Older Australian Adults.

Authors:  Surendra Karki; Anthony T Newall; C Raina MacIntyre; Anita E Heywood; Peter McIntyre; Emily Banks; Bette Liu
Journal:  PLoS One       Date:  2016-08-02       Impact factor: 3.240

8.  The PINE study: rationale and design of a randomised comparison of epidural injection of local anaesthetics and steroids versus care-as-usual to prevent postherpetic neuralgia in the elderly [ISRCTN32866390].

Authors:  Wim Opstelten; Albert JM Van Wijck; Gerrit A Van Essen; Erik Buskens; Annette AA Bak; Cornelis J Kalkman; Theo JM Verheij; Karel GM Moons
Journal:  BMC Anesthesiol       Date:  2004-01-26       Impact factor: 2.217

9.  Streptomycin-lidocaine injections for the treatment of postherpetic neuralgia: Report of three cases with literature review.

Authors:  Shefali Waghray; Shaik Mohammed Asif; Mahesh Kumar Duddu; Gururaj Arakeri
Journal:  Eur J Dent       Date:  2013-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.